Item 8.01. Other Events

On August 18, 2009, Geron Corporation (the "Company") publicly disseminated a press release announcing that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency's review of new nonclinical animal study data submitted by the Company.

The foregoing description is qualified in its entirety by reference to the Company's Press Release dated August 18, 2009, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(c) Exhibits

99.1 Press release dated August 18, 2009.

---